In vitro, R-421 specifically targeted and killed a number of nectin4-positive human malignant cells, representative of clinically relevant nectin4-positive indications, in particular triple negative breast cancers, pancreatic ductal carcinomas, breast and epidermoid carcinomas. Here, NECTIN4 is linked to pancreatic ductal adenocarcinoma.